ARWR — Arrowhead Pharmaceuticals Inc

Ownership history in Siren, L.L.C. · 6 quarters on record

This page tracks every 13F SEC filing in which Siren, L.L.C. reported a position in Arrowhead Pharmaceuticals Inc (ARWR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position

3.6% (2025 Q3)

Avg. % of fund

2.58%

First filed

2024 Q3

Last filed

2025 Q4

Quarters held

6

Quarter	Action	Shares	Change	Chg %	% of Fund	Mkt Value	Price (EOQ)
2025 Q4	REDUCED	1,500,476	-1,169,404	-43.8%	2.97%	$99.6M	$66.39
2025 Q3	UNCHANGED	2,669,880	—	0%	3.60%	$92.1M	$34.49
2025 Q2	UNCHANGED	2,669,880	—	0%	2.18%	$42.2M	$15.80
2025 Q1	REDUCED	2,669,880	-231,801	-8.0%	1.94%	$34.0M	$12.74

% of Fund (quarterly) ARWR price (monthly, adj. close)

Other funds also holding ARWR

As of 2025 Q4 — sorted by position size

Western Financial Corp/CA 3Y 21.6% Avoro Capital Advisors LLC 3Y 7Y 6.93% Privium Fund Management B.V. 3Y 4.87% M28 Capital Management LP 3Y 3.25% WEALTH EFFECTS LLC 3Y 2.98% Slate Path Capital LP 3Y 7Y 2.26% Vestal Point Capital, LP 2.03% Exome Asset Management LLC 1.58% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.55% PLATINUM INVESTMENT MANAGEMENT LTD 3Y 7Y 1.37%

← Back to Siren, L.L.C. Holdings